FibroGen (FGEN) Tops Q4 EPS by 30c

FibroGen (NASDAQ: FGEN) reported Q4 EPS of $0.23, $0.30 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $108.1 million versus the consensus estimate of $72.1 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Goldman "broadly" raises estimates for LTL and truckload stocks